HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HCB101’s engineered macrophage activation and emerging clinical evidence support its potential as a combination backbone, while HCB301 demonstrates the multi-specific engineering capabilities of HanchorBio’s FBDB™ platform
TAIPEI, SHANGHAI, and SAN FRANCISCO — October 27, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
The research highlights HanchorBio’s strategy to advance immunotherapy beyond single-pathway checkpoint blockade by integrating macrophage-mediated tumor clearance with established and emerging cancer treatments.
HCB101: Beyond CD47 Blockade — Engineered for Combination
HCB101 is an engineered SIRPα–IgG4 Fc fusion protein designed to block the CD47–SIRPα innate immune checkpoint while minimizing red blood cell binding.
Unlike CD47 inhibitors incorporating an effector-silenced IgG1 Fc, HCB101 retains macrophage-mediated phagocytic activity through its functional IgG4 Fc-containing architecture. Published preclinical studies demonstrated robust tumor-cell phagocytosis with minimal red blood cell phagocytosis.
This functional distinction provides a scientific rationale for combining HCB101 with therapies that do not provide strong Fc-mediated tumor-opsonizing activity, including PD-1 inhibitors, chemotherapy, anti-angiogenic agents, and HER2/EGFR-directed antibodies.
Emerging clinical evidence supports further evaluation of this strategy. HCB101 monotherapy demonstrated sustained CD47 receptor occupancy and a confirmed partial response in head and neck cancer, with treatment ongoing beyond 83 weeks. In second-line gastric/gastroesophageal junction (GC/GEJ) cancer, HCB101 combined with ramucirumab and paclitaxel achieved a preliminary objective response rate (ORR) of 50.0% (11/22) and disease control rate (DCR) of 100% (22/22). Additional activity was observed in first-line HER2-positive gastric cancer (ORR 77.8%, 7/9) and second-line colorectal cancer (ORR 35.3%, 6/17).
These early, nonrandomized clinical findings support continued evaluation of HCB101 across distinct treatment backbones, with controlled studies needed to establish its incremental therapeutic contribution. Second-line GC/GEJ cancer remains HanchorBio’s lead clinical development priority.
From Clinical Evidence to Partner-Enabled Innovation
Building on this clinical foundation, HanchorBio is exploring next-generation combinations involving PD-1/VEGF bispecific antibodies, antibody-drug conjugates (ADCs), therapeutic cancer vaccines, and small molecules targeting complementary tumor microenvironment pathways.
Its collaboration strategy includes InxMed’s FAK inhibitor IN10018 and a recently signed memorandum of understanding with Aston Sci. involving therapeutic cancer vaccines.
These initiatives reflect HanchorBio’s ambition to develop HCB101 as a versatile macrophage-directed backbone that may complement therapeutic innovation beyond its internal pipeline.
“The next generation of immunotherapy must do more than release inhibitory checkpoints. It must engage complementary immune mechanisms that can work together,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “With HCB101, we have engineered a molecule that goes beyond CD47 blockade to support macrophage-mediated tumor clearance while minimizing red blood cell interactions. Our emerging clinical evidence supports development across multiple treatment combinations, from established standards of care to bispecific antibodies, ADCs, and cancer vaccines. Through our FBDB™ platform and expanding collaborations, we aim to translate this differentiated biology into broader therapeutic opportunities.”
FBDB™: Extending Innate Immunity Through Multi-Specific Engineering
HanchorBio’s proprietary Fc-Based Designer Biologics (FBDB™) platform combines protein engineering, Fc-function optimization, and multi-specific molecular design to develop therapies addressing complementary immune mechanisms.
HCB301 exemplifies this approach through a trispecific fusion protein that integrates SIRPα, PD-L1, and TGFβ pathway modulation into a single molecule, designed to address innate immune suppression, adaptive checkpoint resistance, and tumor microenvironment regulation.
A scientific poster featuring early HCB301 Phase 1 findings will be presented by a study investigator at ESMO Congress 2026. The study’s clinical safety findings and therapeutic window require further evaluation.
ESMO Congress 2026 — Scientific Abstracts
HCB101 — Three Accepted ePoster Abstracts
- HCB101 Plus Ramucirumab and Paclitaxel in Second-line Advanced Gastric Cancer: Results From a Phase 1b/2a Trial
- HCB101 as a Cross-GI Innate Immune Backbone: Clinical Validation in Gastric Cancer and Early Extension to Colorectal Cancer
- HCB101 as an Innate Immune Backbone for PD-1-Based Combinations: Early Clinical Signals in HNSCC and TNBC
HCB301 — Scientific Poster Presentation
- HCB301-101: Early Safety and Disease Control From a Phase 1 Study of a Tri-Functional SIRPα/PD-L1/TGF-β Biologic in Advanced Solid Tumors
All four abstracts received acceptance notifications. The congress will include the HCB301 study, while the three HCB101 ePosters will not be included in the final scientific program.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB™ platform. Powered by a multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. Operating across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy for patients worldwide.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s investigational products, platform technologies, potential therapeutic applications, clinical development, combination strategies, and strategic collaborations.
These statements involve scientific, clinical, regulatory, operational, and commercial risks and uncertainties. Preliminary clinical and preclinical findings may not predict outcomes in subsequent studies. The safety, efficacy, and incremental therapeutic contribution of HanchorBio’s investigational products and proposed combinations have not been established in adequately controlled clinical trials. Future development activities and collaborations are subject to additional research, regulatory requirements, and applicable agreements.
Except as required by applicable law, HanchorBio undertakes no obligation to update these statements.
HanchorBio Business Development Contact:
Email: [email protected]
Investor & Media Contact:
Email: [email protected]
漢康生技四篇科學摘要獲 ESMO 2026 年會接受 展現差異化免疫治療研發策略
HCB101 透過工程化設計強化巨噬細胞活化功能，結合初步臨床證據支持其作為聯合治療骨幹的開發潛力；HCB301 則展現漢康生技 FBDB™ 平台的多特異性分子工程能力
【台北、上海、舊金山，2026 年 10 月 27 日】－全球臨床階段生技公司漢康生技（TWSE：7827）今日宣布，旗下 HCB101 與 HCB301 共四篇科學研究摘要獲得 2026 年歐洲腫瘤內科學會年會（ESMO Congress 2026）接受。該年會於 10 月 23 日至 27 日在西班牙馬德里舉行。
本次研究成果突顯漢康生技致力於突破單一路徑免疫檢查點阻斷的治療策略，透過結合巨噬細胞介導的腫瘤清除機制與現有及新興癌症治療方式，推動下一代免疫治療的發展。
HCB101：超越 CD47 阻斷機制，專為聯合治療設計
HCB101 是一款經工程化設計的 SIRPα–IgG4 Fc 融合蛋白，旨在阻斷 CD47–SIRPα 先天免疫檢查點，同時降低與紅血球的結合。
不同於採用效應功能靜默化 IgG1 Fc 設計的 CD47 抑制劑，HCB101 透過保有功能性 IgG4 Fc 的分子架構，維持巨噬細胞介導的吞噬活性。已發表的臨床前研究顯示，HCB101 能有效促進巨噬細胞吞噬腫瘤細胞，同時將紅血球吞噬作用降至最低。
此一功能性差異，為 HCB101 與其他不具強效 Fc 介導腫瘤調理作用的治療方式聯合使用，提供科學依據，包括 PD-1 抑制劑、化學治療、抗血管新生藥物，以及 HER2／EGFR 標靶抗體等。
逐步累積的初步臨床證據，也支持進一步評估此一聯合治療策略。HCB101 單藥治療已觀察到持續性的 CD47 受體占有率，並於一名頭頸癌病人中確認部分緩解（PR），且持續接受治療超過 83 週。
在二線胃癌/胃食道交界部癌（GC/GEJ）方面，HCB101 聯合雷莫蘆單抗（ramucirumab）及紫杉醇（paclitaxel）的治療方案，初步客觀緩解率（ORR）達 50.0%（11/22），疾病控制率（DCR）達 100%（22/22）。
此外，在一線 HER2 陽性胃癌及二線大腸直腸癌（CRC）中，亦觀察到初步臨床活性，客觀緩解率分別為 77.8%（7/9）及 35.3%（6/17）。
上述早期、非隨機分組臨床研究結果，支持持續評估 HCB101 與不同治療方案聯合使用的潛力；然而，仍需透過對照性臨床研究，進一步確認 HCB101 在聯合治療中的額外治療貢獻。目前，二線胃癌/胃食道交界部癌仍為漢康生技優先推進的臨床開發重點。
從臨床證據延伸至策略合作，拓展創新聯合治療
基於現有臨床研究基礎，漢康生技正積極探索新一代聯合治療策略，包括 PD-1／VEGF 雙特異性抗體、抗體藥物複合體（ADC）、治療性癌症疫苗，以及針對腫瘤微環境互補性作用路徑的小分子藥物。
相關合作布局包括與應世生物（InxMed）合作探索其 FAK 抑制劑 IN10018，以及近期與 Aston Sci. 簽署合作備忘錄，共同探索治療性癌症疫苗的應用潛力。
上述合作反映漢康生技致力於將 HCB101 開發為具備廣泛應用潛力的巨噬細胞導向聯合治療骨幹，使其不僅能與公司內部產品管線形成互補，也有機會結合外部創新治療技術，拓展更多治療應用。
漢康生技創辦人、董事長暨執行長劉世高博士表示：「下一代免疫治療不能僅止於解除免疫檢查點的抑制，更需要整合能夠相互協同的免疫機制。透過 HCB101 的工程化分子設計，我們不僅實現 CD47 阻斷，更能支持巨噬細胞介導的腫瘤清除作用，同時降低與紅血球的交互作用。目前逐步累積的臨床證據，支持我們持續探索 HCB101 與多種治療方式的聯合應用，從現有標準治療，到雙特異性抗體、ADC 及癌症疫苗。透過 FBDB™ 平台及持續拓展的策略合作，我們期望將這些差異化生物學機制轉化為更廣泛的治療機會。」
FBDB™ 平台：透過多特異性分子工程，拓展先天免疫治療應用
漢康生技自主研發的 Fc-Based Designer Biologics（FBDB™）平台，整合蛋白質工程、Fc 功能優化及多特異性分子設計技術，致力於開發可同時作用於互補性免疫機制的新一代生物藥物。
HCB301 即為此平台技術的代表性產品之一。作為一款三特異性融合蛋白，HCB301 將 SIRPα、PD-L1 及 TGFβ 三種作用路徑整合於單一分子中，旨在同時調節先天免疫抑制、適應性免疫檢查點抗性及腫瘤微環境。
HCB301 第一期臨床試驗的早期研究結果，將由臨床研究者於 ESMO 2026 年會以科學海報形式發表。目前相關臨床安全性結果及治療窗口仍有待進一步評估。
ESMO 2026 年會科學研究摘要
HCB101：三篇獲接受的電子海報（ePoster）摘要
- HCB101 聯合雷莫蘆單抗與紫杉醇用於二線晚期胃癌治療：第一期 b／第二期 a 臨床試驗結果
HCB101 Plus Ramucirumab and Paclitaxel in Second-line Advanced Gastric Cancer: Results From a Phase 1b/2a Trial
- HCB101 作為跨消化道癌症的先天免疫治療骨幹：胃癌臨床驗證及初步拓展至大腸直腸癌
HCB101 as a Cross-GI Innate Immune Backbone: Clinical Validation in Gastric Cancer and Early Extension to Colorectal Cancer
- HCB101 作為 PD-1 聯合治療的先天免疫治療骨幹：頭頸部鱗狀細胞癌與三陰性乳癌的早期臨床訊號
HCB101 as an Innate Immune Backbone for PD-1-Based Combinations: Early Clinical Signals in HNSCC and TNBC
HCB301：科學海報發表
- HCB301-101：三功能 SIRPα／PD-L1／TGF-β 生物製劑用於晚期實體腫瘤第一期臨床試驗的早期安全性與疾病控制結果
HCB301-101: Early Safety and Disease Control From a Phase 1 Study of a Tri-Functional SIRPα/PD-L1/TGF-β Biologic in Advanced Solid Tumors
四篇研究摘要均已收到接受通知。本屆年會的最終科學議程將納入 HCB301 研究海報，HCB101 的三篇電子海報則不列入最終科學議程。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司，致力於透過自主研發的 FBDB™ 平台，開發針對癌症及免疫介導疾病的新一代生物藥物。憑藉多功能蛋白質工程技術，公司產品管線涵蓋 HCB101、HCB301 及 HCB303。漢康生技於台北、美國舊金山灣區及上海設有營運據點，致力於重新定義免疫治療，為全球病人創造更多治療可能。
前瞻性聲明
本新聞稿包含有關漢康生技研究中產品、平台技術、潛在治療應用、臨床開發、聯合治療策略及策略合作的前瞻性聲明。
此類聲明涉及科學、臨床、法規、營運及商業等方面的風險與不確定性。初步臨床及臨床前研究結果未必能預測後續研究的結果。漢康生技研究中產品及擬議聯合治療方案的安全性、有效性與額外治療